Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M, Bertram U, Peter K, Bode C, Ruef J. Moser M, et al. Among authors: ruef j. J Cardiovasc Pharmacol. 2003 Apr;41(4):586-92. doi: 10.1097/00005344-200304000-00011. J Cardiovasc Pharmacol. 2003. PMID: 12658060
Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Kranzhofer R, Ruef J. Kranzhofer R, et al. Among authors: ruef j. Platelets. 2006 May;17(3):163-9. doi: 10.1080/09537100500441101. Platelets. 2006. PMID: 16702043
Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Bertram U, et al. Among authors: ruef j. J Thromb Thrombolysis. 2002 Dec;14(3):197-203. doi: 10.1023/a:1025044625487. J Thromb Thrombolysis. 2002. PMID: 12913399
New antithrombotic drugs on the horizon.
Ruef J, Katus HA. Ruef J, et al. Expert Opin Investig Drugs. 2003 May;12(5):781-97. doi: 10.1517/13543784.12.5.781. Expert Opin Investig Drugs. 2003. PMID: 12720490 Review.
Closure of guide wire-induced coronary artery perforation with a two-component fibrin glue.
Störger H, Ruef J. Störger H, et al. Among authors: ruef j. Catheter Cardiovasc Interv. 2007 Aug 1;70(2):237-40. doi: 10.1002/ccd.21115. Catheter Cardiovasc Interv. 2007. PMID: 17420994
Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study).
Ruef J, März W, Winkelmann BR. Ruef J, et al. Scand Cardiovasc J. 2006 Oct;40(5):274-9. doi: 10.1080/14017430600925300. Scand Cardiovasc J. 2006. PMID: 17012137
Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention.
Haase J, Bayar R, Hackenbroch M, Störger H, Hofmann M, Schwarz CE, Reinemer H, Schwarz F, Ruef J, Sommer T. Haase J, et al. Among authors: ruef j. J Interv Cardiol. 2004 Dec;17(6):367-73. doi: 10.1111/j.1540-8183.2004.04078.x. J Interv Cardiol. 2004. PMID: 15546288
The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation.
Ruef J, Kuehnl P, Meinertz T, Merten M. Ruef J, et al. Platelets. 2008 Aug;19(5):359-64. doi: 10.1080/09537100802105040. Platelets. 2008. PMID: 18791942
Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C. Moser M, et al. Among authors: ruef j. J Thromb Thrombolysis. 2001 Oct;12(2):165-9. doi: 10.1023/a:1012975522037. J Thromb Thrombolysis. 2001. PMID: 11729368 Clinical Trial.
Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
Moser M, Nordt T, Peter K, Ruef J, Kohler B, Schmittner M, Smalling R, Kübler W, Bode C. Moser M, et al. Among authors: ruef j. Circulation. 1999 Nov 2;100(18):1858-64. doi: 10.1161/01.cir.100.18.1858. Circulation. 1999. PMID: 10545429 Clinical Trial.
57 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page